866-997-4948(US-Canada Toll Free)

Hepatitis C - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Diseases & Conditions

No. of Pages : 722 Pages

Global Markets Direct’s, ‘Hepatitis C - Pipeline Review, H1 2014’, provides an overview of the Hepatitis C’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hepatitis C
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hepatitis C and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hepatitis C pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hepatitis C
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Introduction

Hepatitis C Overview
Therapeutics Development
Hepatitis C - Therapeutics under Development by Companies
Hepatitis C - Therapeutics under Investigation by Universities/Institutes
Hepatitis C - Pipeline Products Glance
Hepatitis C - Products under Development by Companies
Hepatitis C - Products under Investigation by Universities/Institutes
Hepatitis C - Companies Involved in Therapeutics Development
Hepatitis C - Therapeutics Assessment
Drug Profiles
Hepatitis C - Recent Pipeline Updates
Hepatitis C - Dormant Projects
Hepatitis C - Discontinued Products
Hepatitis C - Product Development Milestones

Appendix

List of Table


Number of Products under Development for Hepatitis C, H1 2014
Number of Products under Development for Hepatitis C - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Development by Companies, H1 2014 (Contd..3)
Number of Products under Development by Companies, H1 2014 (Contd..4)
Number of Products under Development by Companies, H1 2014 (Contd..5)
Number of Products under Development by Companies, H1 2014 (Contd..6)
Number of Products under Development by Companies, H1 2014 (Contd..7)
Number of Products under Development by Companies, H1 2014 (Contd..8)
Number of Products under Development by Companies, H1 2014 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Comparative Analysis by Unknown Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Development by Companies, H1 2014 (Contd..2)
Products under Development by Companies, H1 2014 (Contd..3)
Products under Development by Companies, H1 2014 (Contd..4)
Products under Development by Companies, H1 2014 (Contd..5)
Products under Development by Companies, H1 2014 (Contd..6)
Products under Development by Companies, H1 2014 (Contd..7)
Products under Development by Companies, H1 2014 (Contd..8)
Products under Development by Companies, H1 2014 (Contd..9)
Products under Development by Companies, H1 2014 (Contd..10)
Products under Development by Companies, H1 2014 (Contd..11)
Products under Development by Companies, H1 2014 (Contd..12)
Products under Development by Companies, H1 2014 (Contd..13)
Products under Development by Companies, H1 2014 (Contd..14)
Products under Development by Companies, H1 2014 (Contd..15)
Products under Development by Companies, H1 2014 (Contd..16)
Products under Investigation by Universities/Institutes, H1 2014
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H1 2014
Hepatitis C - Pipeline by Johnson & Johnson, H1 2014
Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H1 2014
Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014
Hepatitis C - Pipeline by United Therapeutics Corporation, H1 2014
Hepatitis C - Pipeline by GlaxoSmithKline plc, H1 2014
Hepatitis C - Pipeline by Tekmira Pharmaceuticals Corp., H1 2014
Hepatitis C - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Idenix Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Gilead Sciences, Inc., H1 2014
Hepatitis C - Pipeline by Biotest AG, H1 2014
Hepatitis C - Pipeline by Merck & Co., Inc., H1 2014
Hepatitis C - Pipeline by Lentigen Corporation, H1 2014
Hepatitis C - Pipeline by BioLineRx, Ltd., H1 2014
Hepatitis C - Pipeline by Biotron Limited, H1 2014
Hepatitis C - Pipeline by Novartis AG, H1 2014
Hepatitis C - Pipeline by Achillion Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014
Hepatitis C - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014
Hepatitis C - Pipeline by Pfizer Inc., H1 2014
Hepatitis C - Pipeline by Astex Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014
Hepatitis C - Pipeline by Genmab A/S, H1 2014
Hepatitis C - Pipeline by Koronis Pharma, Inc., H1 2014
Hepatitis C - Pipeline by Santaris Pharma A/S, H1 2014
Hepatitis C - Pipeline by Tacere Therapeutics, Inc., H1 2014
Hepatitis C - Pipeline by Crucell N.V., H1 2014
Hepatitis C - Pipeline by Celgene Corporation, H1 2014
Hepatitis C - Pipeline by XTL Biopharmaceuticals Ltd., H1 2014
Hepatitis C - Pipeline by Hemispherx Biopharma, Inc., H1 2014
Hepatitis C - Pipeline by Immtech Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Immunomedics, Inc., H1 2014
Hepatitis C - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Medivir AB, H1 2014
Hepatitis C - Pipeline by Patrys Limited, H1 2014
Hepatitis C - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Amarillo Biosciences, Inc., H1 2014
Hepatitis C - Pipeline by Flamel Technologies S.A., H1 2014
Hepatitis C - Pipeline by Transgene SA, H1 2014
Hepatitis C - Pipeline by Xenetic Biosciences plc, H1 2014
Hepatitis C - Pipeline by HanAll Biopharma Co., Ltd., H1 2014
Hepatitis C - Pipeline by LG Life Sciences, Ltd., H1 2014
Hepatitis C - Pipeline by Theravance, Inc., H1 2014
Hepatitis C - Pipeline by Summit Corporation plc, H1 2014
Hepatitis C - Pipeline by Phynova Group Ltd, H1 2014
Hepatitis C - Pipeline by Microbio Co., Ltd., H1 2014
Hepatitis C - Pipeline by ChronTech Pharma AB, H1 2014
Hepatitis C - Pipeline by Raptor Pharmaceuticals Corp., H1 2014
Hepatitis C - Pipeline by NeuroVive Pharmaceutical AB, H1 2014
Hepatitis C - Pipeline by Digna Biotech, S.L., H1 2014
Hepatitis C - Pipeline by Debiopharm International S.A., H1 2014
Hepatitis C - Pipeline by StemCells, Inc., H1 2014
Hepatitis C - Pipeline by Scynexis, Inc., H1 2014
Hepatitis C - Pipeline by Bionor Pharma ASA, H1 2014
Hepatitis C - Pipeline by IMGENEX Corporation, H1 2014
Hepatitis C - Pipeline by ImmunoBiology Ltd., H1 2014
Hepatitis C - Pipeline by Medipol SA, H1 2014
Hepatitis C - Pipeline by Altor BioScience Corporation, H1 2014
Hepatitis C - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by PT Bio Farma, H1 2014
Hepatitis C - Pipeline by Eiger BioPharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by AiCuris GmbH & Co. KG, H1 2014
Hepatitis C - Pipeline by Okairos AG, H1 2014
Hepatitis C - Pipeline by PTC Therapeutics, Inc., H1 2014
Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc., H1 2014
Hepatitis C - Pipeline by Kineta, Inc., H1 2014
Hepatitis C - Pipeline by Presidio Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Romark Laboratories, L.C., H1 2014
Hepatitis C - Pipeline by Chimerix, Inc., H1 2014
Hepatitis C - Pipeline by REPLICor Inc., H1 2014
Hepatitis C - Pipeline by Concert Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Immunotope, Inc., H1 2014
Hepatitis C - Pipeline by GeneCure LLC, H1 2014
Hepatitis C - Pipeline by Microbiotix, Inc., H1 2014
Hepatitis C - Pipeline by Bolder Biotechnology, Inc., H1 2014
Hepatitis C - Pipeline by Oncolys BioPharma Inc., H1 2014
Hepatitis C - Pipeline by Globeimmune, Inc., H1 2014
Hepatitis C - Pipeline by Janssen Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Immunocore Limited, H1 2014
Hepatitis C - Pipeline by Enanta Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Canopus BioPharma Incorporated, H1 2014
Hepatitis C - Pipeline by Seek, H1 2014
Hepatitis C - Pipeline by Quintessence Biosciences, Inc., H1 2014
Hepatitis C - Pipeline by Epiphany Biosciences, Inc., H1 2014
Hepatitis C - Pipeline by Alios BioPharma, Inc., H1 2014
Hepatitis C - Pipeline by CureTech Ltd., H1 2014
Hepatitis C - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2014
Hepatitis C - Pipeline by VBI Vaccines, H1 2014
Hepatitis C - Pipeline by PharmaEssentia Corporation, H1 2014
Hepatitis C - Pipeline by NasVax Ltd., H1 2014
Hepatitis C - Pipeline by iQur Ltd., H1 2014
Hepatitis C - Pipeline by Regulus Therapeutics Inc., H1 2014
Hepatitis C - Pipeline by Rodos BioTarget GmbH, H1 2014
Hepatitis C - Pipeline by AIMM Therapeutics B.V., H1 2014
Hepatitis C - Pipeline by Sorrento Therapeutics, Inc., H1 2014
Hepatitis C - Pipeline by Cocrystal Discovery, Inc., H1 2014
Hepatitis C - Pipeline by Profectus BioSciences, Inc., H1 2014
Hepatitis C - Pipeline by 3-V Biosciences, Inc., H1 2014
Hepatitis C - Pipeline by DiscoveryBiomed, Inc., H1 2014
Hepatitis C - Pipeline by Ascendis Pharma A/S, H1 2014
Hepatitis C - Pipeline by ViroLogik GmbH, H1 2014
Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H1 2014
Hepatitis C - Pipeline by B&C Biopharm, H1 2014
Hepatitis C - Pipeline by Pfenex Inc., H1 2014
Hepatitis C - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Therapure Biopharma Inc., H1 2014
Hepatitis C - Pipeline by NAL Pharmaceuticals Ltd., H1 2014
Hepatitis C - Pipeline by DEKK-TEC, Inc., H1 2014
Hepatitis C - Pipeline by iTherX, Inc., H1 2014
Hepatitis C - Pipeline by AUS Bio Limited, H1 2014
Hepatitis C - Pipeline by SomaGenics Inc., H1 2014
Hepatitis C - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Nexigen GmbH, H1 2014
Hepatitis C - Pipeline by Sumagen Co., Ltd., H1 2014
Hepatitis C - Pipeline by Delpor, Inc., H1 2014
Hepatitis C - Pipeline by Hepacyl Therapeutics, SL, H1 2014
Hepatitis C - Pipeline by Rottapharm|Madaus, H1 2014
Hepatitis C - Pipeline by Xiamen Amoytop Biotech Co., Ltd., H1 2014
Hepatitis C - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014
Hepatitis C - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014
Hepatitis C - Pipeline by American Gene Technologies International Inc., H1 2014
Hepatitis C - Pipeline by GinkgoPharma Co. Ltd., H1 2014
Hepatitis C - Pipeline by Vaxeal Holding SA, H1 2014
Hepatitis C - Pipeline by Conkwest, Inc., H1 2014
Hepatitis C - Pipeline by ARA Healthcare Pvt. Ltd., H1 2014
Hepatitis C - Pipeline by Biota Pharmaceuticals, Inc., H1 2014
Hepatitis C - Pipeline by Biocad, H1 2014
Hepatitis C - Pipeline by Humabs BioMed SA, H1 2014
Hepatitis C - Pipeline by AbbVie Inc., H1 2014
Hepatitis C - Pipeline by Hependo Sp. z o. o. (Ltd), H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Hepatitis C Therapeutics - Recent Pipeline Updates, H1 2014
Hepatitis C - Dormant Projects, H1 2014
Hepatitis C - Discontinued Products, H1 2014

List of Chart


Number of Products under Development for Hepatitis C, H1 2014
Number of Products under Development for Hepatitis C - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *